Drug Trial Radar · NCT07537387
A Study on the Pursuit of Sustained Clearance of HBsAg in Chronic Hepatitis B(CHB) Patients With Previous Interferon Treatment Using Pegylated Interferon Alpha
Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
10,000
Planned (sponsor's estimate)
Start
Apr 30, 2026
Primary completion
Dec 31, 2029
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- xieqingAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 17, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
Summary
As written by the sponsor on the registry.
This is a real-world, prospective, multicenter, non-randomized, controlled study. It aims to investigate the efficacy and safety of pegylated interferon α-2b (PEG IFN α-2b) monotherapy versus its combination with nucleos(t)ide analogs (NAs) regarding hepatitis B surface antigen (HBsAg) clearance in interferon-experienced patients with chronic hepatitis B (CHB). Subjects will receive either interferon-based therapy or NAs monotherapy based on their personal willingness and physicians' professional recommendations, with a uniform 48-week treatment course for all enrolled patients.
Conditions
- Chronic Hepatitis b
Interventions
PEG IFNα-2b monotherapy or combination therapy with NAsDrug
Peginterferon α-2b injection, 180mcg, s.c, once a week, for 48 weeks.If HBV DNA is below the lower limit of detection at baseline (highly sensitive assay is recommended), PEG IFNα-2b monotherapy will be administered.
NAs monotherapy groupDrug
Peginterferon α-2b injection, 180mcg, s.c, once a week, for 48 weeks.If HBV DNA is below the lower limit of detection at baseline (highly sensitive assay is recommended), PEG IFNα-2b monotherapy will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects with undetectable HBsAgTime frame: Week 48
- Percentage of subjects with undetectable HBV DNATime frame: Week 48
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.